Stock Events

Stock Events

Living Cell Technologies 

$0.030600
11
+$0.00+0% Tuesday 19:57

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30JunExpected
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
-0
-0
-0
0
Expected EPS
0
Actual EPS
-0.0006

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-1.52MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a major player in the pharmaceutical industry, directly competing in several therapeutic areas with Algorae.
Merck
MRK
Mkt Cap305.12B
Merck operates globally in many of the same segments as Algorae, including oncology and vaccines.
Novartis
NVS
Mkt Cap293.94B
Novartis competes in the research and development of innovative medicines similar to Algorae's offerings.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline has a broad portfolio in pharmaceuticals, directly competing with Algorae in multiple drug categories.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has significant overlap with Algorae in areas like immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson's pharmaceutical division offers products that compete across a range of therapeutic areas covered by Algorae.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on innovative therapeutics, similar to Algorae, particularly in areas like oncology and cardiovascular disease.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb competes with Algorae in the development of prescription drugs and biologics.
Sanofi
SNY
Mkt Cap104.13B
Sanofi operates globally in pharmaceuticals, competing directly with Algorae in areas such as diabetes and cardiovascular health.
Roche
RHHBY
Mkt Cap334.28B
Roche's pharmaceutical division is a direct competitor in several of Algorae's key focus areas, including oncology and immunology.

About

Biotechnology
Health Technology
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Show more...
CEO
Ken Taylor
Employees
48
Country
United States
ISIN
US53838R1077
WKN
000A0YGYX

Listings

AU
AU
1AI.AU
STU
DE
LHI0.STU
STU
DE
LHI.STU
OTC Link
US
LVCLF

0 Comments

Share your thoughts

FAQ

What is Living Cell Technologies stock price today?▼
The current price of LVCLY is $0.03 USD — it has increased by +0% in the past 24 hours. Watch Living Cell Technologies stock price performance more closely on the chart.
What is Living Cell Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Living Cell Technologies stocks are traded under the ticker LVCLY.
What were Living Cell Technologies earnings last quarter?▼
LVCLY earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Living Cell Technologies revenue for the last year?▼
Living Cell Technologies revenue for the last year amounts to 0 USD.
What is Living Cell Technologies net income for the last year?▼
LVCLY net income for the last year is -1.52M USD.
How many employees does Living Cell Technologies have?▼
As of August 09, 2026, the company has 48 employees.
In which sector is Living Cell Technologies located?▼
Living Cell Technologies operates in the Technology sector.
When did Living Cell Technologies complete a stock split?▼
Living Cell Technologies has not had any recent stock splits.
Where is Living Cell Technologies headquartered?▼
Living Cell Technologies is headquartered in Melbourne, United States.